CM
Compass Therapeutics, Inc.
CMPX · NASDAQ
$2.18 -1.80% (-$0.04)
1M +0.45%
Market Cap $392.6M
P/E Ratio -
Div. Yield -
ROE 38.71%
Bulios Fair Price
$1.71
21.6% downside
Current Price
$2.18
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CMPX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
78 /100
Cheap P/B 2.36x
P/FFO N/A
P/S N/A
Growth
39 /100
Stable Book val. growth 2.71%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 38.71%
ROA 38.62%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 11.22x
Debt/Equity 0.06x
Net debt/EBITDA N/A
Stability
80 /100
Stable EPS volatility 11.38%
Profitable years 0
Beta 0.82x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CMPX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Thomas J. Schuetz
Employees
39
Headquarters
Boston
Upcoming events
04 NOV
Earnings
Upcoming earnings report